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THE ROLES OF LYMPHOTOXIN AND TUMOR NECROSIS FACTOR-ALPHA IN THE 
PATHOGENESIS OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS. Sonia 
Friedman and Nancy H. Ruddle, Department of Epidemiology and Public 
Health, New Haven, CT. 
Multiple sclerosis (MS) is a progressively debilitating inflammatory 
disease of the central nervous system (CNS). Although the etiology of MS 
is unclear, the cytokines tumor necrosis factor-alpha (TNF-a) and 
lymphotoxin (LT) have recently been implicated in its pathogenesis. To 
examine the roles of LT and TNF-a , we worked with experimental allergic 
encephalomyelitis (EAE), a murine model of MS in which the host animal is 
induced to mount an immune attack to myelin basic protein (MBP). EAE is 
characterized by invasion of the CNS with lymphocytes leading to 
demyelination histologically and paralysis clinically. We induced EAE in 
SJL/J mice by injecting LNC-8 or VB17' cells, MBP-specific CD4+ T cell 
lines known to secrete LT and TNF-a and derived from the popliteal lymph 
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nodes of an SJLVJ mouse immunized with porcine MBP. We used Di-I-C, a 
new and highly effective specific cell label, to explore the timing of T cell 
entry into the CNS and T cell migration and distribution within the CNS in 
EAE. We then used TN3.19.12, a newly developed hamster monoclonal 
anti-LT/TNF-a antibody, to block the clinical induction of EAE and to 
examine the histological effects of EAE alleviation. Our experiments 
showed that Di-I-C did not interfere with transfer of EAE; the average day 
of onset and average clinical disease score of mice injected with dyed 
cells (7.2 and 2.5) were comparable to those of mice injected with undyed 
cells (6.7 and 2.2). TN3.19.12, when injected 48 hours after dyed cells, 
alleviated severity of EAE (day of onset: 4.7, maximum score: 1.0). 
Histological analysis revealed Di-I-C labelled T cells thoughout the brain 
and spinal cord 8 hours post injection (score = 2+). T infiltration peaked 
> 
at 11 hours post injection (score= 4+), dwindled by 12 hours post injection 
(score = 1+) and disappeared by 18 hours post injection. Hematoxylin and 
eosin stained sections of brain and spinal cord from mice with advanced 
clinical disease showed marked perivascular infiltration of inflammatory 
cells. This infiltration was much reduced in antibody injected animals. 
These results suggest that clinical signs of EAE occur long after T cells 

specific for MBP have entered and left the CNS. TN3.19.12 probably 
alleviates disease by blocking the actions of soluble LT and TNF-a and 
thus may be important in inhibiting inflammatory cell recruitment, and 
preventing alterations in blood brain barrier permeability. 

Introduction 
Multiple sclerosis (MS) is an inflammatory disease of the central 
nervous system (CNS) characterized by primary destruction of myelin. It 
affects scattered areas of the CNS but most often plaques are seen in 
periventricular white matter, brainstem, spinal cord, and optic nerves. 
These plaques are charaterized by destruction of myelin sheaths with 
preservation of axons and death of oligodendrocytes within the center of 
the lesion. During early plaque development, perivascular inflammatory 
cells such as lymphocytes, plasma cells, and macrophages pass through 
the blood brain barrier to invade the substance of the white matter and 
are thought to play a critical role in myelin destruction. In later plaque 
evolution, astrocytes produce extensive gliosis and oligodendrocytes 
undergo hyperplasia at the edges of the plaque (Raine et. al., 1981) and 
make ineffective attempts at remyelination (Rodriguez, 1989). 
The pathogenesis of MS is unclear but the most widely considered 
hypothesis, the "autoimmune" theory, is that MS is the result of an 
immune reaction against self CNS antigens, particularly those present on 
oligodendrocytes, the cells in the CNS that make myelin. T cells are 
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thought to enter the CNS through endothelial cells of the blood brain 
barrier and to react with normal white matter. It is not known why in MS 
that previously harmless CD4+ T cells suddenly become activated against 
self. Since in MS lesions, endothelial cells and astrocytes are known to 
express class II MHC molecules, it is possible that they could present the 
myelin antigens to CD4+ T cells. These T cells would then be activated 
against self antigens and could recruit lymphokines and macrophages to 
help mediate myelin destruction (Rodriguez, 1989). It is not known why 
endothelial cells and astrocytes upregulate class II MHC molecules in MS 
and if they present self CNS antigens. 
Another important hypothesis, called the "bystander" hypothesis is 
that myelin is an innocent bystander in MS and that it is destroyed as a 
consequence of an immune response occurring within the CNS. This 
hypothesis could explain why different viruses can induce demyelination 
in the nervous system of rodents (Rodriguez, 1989) and why etiologic 
agents such as measles virus (Haase et al., 1989) have reportedly been 
found in MS brains. Perhaps viruses or other infectious agents frequently 
invade the CNS and T lymphocytes and macrophages are recruited to 
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defend against infection. In the process of clearance of virus by T cells, 
myelin may be destroyed nonspecifically by lymphokines or neutral 
proteases released by activated macrophages (Rodriguez, 1989). In 
addition, there may be non-specific migration into the CNS by T cells 
activated against antigens not found in the CNS. Such T cells could cross 
react with CNS antigens. Also, the mode of egress of T cells from the 
CNS is ill-defined. If they cannot find their way readily out of the CNS 
parenchyma, T cells may continue to induce inflammation and myelin 
breakdown. 
These theories about the pathogenesis of MS brush over two very 
complex issues. Since the CNS parenchyma of a healthy individual is an 
"immunologically priveleged" site with few lymphocytes (Traugott, 1985) 
and undetectable MHC molecules (Hickey, 1991), it is difficult to explain 
the detection of antigens and the initiation of inflammation within the 
CNS. First, it is unknown how and when lymphocytes cross the blood brain 
barrier and second it is unknown how lymphocytes and/or macrophages 
mediate inflammation and myelin destruction. 
Recently, it has been suggested that the cytokines TNF-a and 
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lymphotoxin (LT; TNF-B) may play a role in the pathogenesis of several 
human neurologic diseases including MS. LT and TNF-a are closely 
related factors with extensive sequence homology and each has activities 
that could cause inflammation and demyelination. TNF-a is produced by 
macrophages after stimulation with lipopolysaccharide (LPS) and both LT 
and TNF-a are released by T cells activated by antigen or by infection 
with some viruses, including human T cell leukemia virus (HTLV-1) (Paul, 
1988). Both LT and TNF-a have been associated with cachexia (Beutler, 
1986) and TNF-a has been implicated in the pathogenesis of cerebral 
malaria. More importantly, TNF-a is cytotoxic for oligodendrocytes in 
culture and induces a delayed onset degradation of myelin in organotypic 
culture of nervous tissue (Selmaj et al., 1988). Oligodendrocytes in 
culture are even more sensitive to LT (Selmaj et al., 1991). 
LT and TNF-a have also been detected in the brains of MS patients. 
Anti-TNF-a mouse monoclonal and rabbit polyclonal antibodies label 
macrophages and astrocytes at MS lesion sites (Plofman et al., 1989). 
Selmaj et al. have shown for the first time evidence that LT, as well as 
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TNF-a, is present at MS lesions. In their most recent experiments, 
Selmaj et al. demonstrate that antibodies to LT react with CD3+ 
lymphocytes and microglial cells in active lesions whereas antibodies to 
TNF-a react with astrocytes and macrophages in active lesions and with 
occasional endothelial cells at the edges of acute lesions (Selmaj et al., 
1991). Thus, many different cell types may secrete these cytokines and 
induce inflammation and demyelination at MS lesion sites. 
Even more interesting is the fact that LT and TNF-a may initiate and 
even perpetuate the breakdown of the normally intact blood brain barrier. 
LT and TNF-a can interact with endothelial cells and activate the 
endothelium of postcapillary venules. If cerebral endothelial cells 
respond in this way, enhanced lymphocyte adhesion (Cavender et al., 
1989), increased expression of adhesion molecules such as ICAM-1 (Pober 
et al., 1987) and increased permeability (Shijo et al., 1989) could occur at 
the blood brain barrier. LT and TNF-a can also activate monocytes and 
induce the synthesis of a variety of other cytokines such as 
granulocyte-macrophage colony-stimulating factor and macrophage 
colony-stimulating factor and in this way perpetuate the 
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immunopathological process (Selmaj et al., 1991). 
Perhaps one of the most striking examples of the potential 
importance of LT and TNF-a in the pathogenesis of MS is the work of 
Ruddle et al. on experimental allergic encephalomyelitis (EAE). A murine 
model of MS, EAE is an autoimmune condition in which the host animal is 
induced to mount an immune attack to myelin basic protein (MBP), a major 
protein component of CNS myelin. It is characterized by invasion of the 
CNS with lymphocytes leading to demyelination histologically and 
paralysis clinically. The disease occurs after injection of the host 
animal with an emulsion of antigen (spinal cord components) or after 
passively transfering CD4+ T cells specific for MBP or proteolipid protein 
(Traugott et al., 1985). There is a limited heterogeneity of T cell 
receptors from CD4+ lymphocytes that mediate EAE with the majority of 
lymphocytes recognizing the N-terminal MBP-nonapeptide in association 
with l-Au and using the VR8 gene element in PL/J mice. In SJL7J mice, 
most T lymphocytes recognize internal peptides and use VB4, VB17 and 
other gene elements. (Acha-Orbea et al., 1988). 
In earlier in vitro experiments from the Ruddle lab that implicated a 
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role for LT and TNF-a in EAE, researchers used a series of MBP-reactive 
PL/J T cell clones that had identical antigen fine specificity and MHC 
restriction, used the same TCR VB gene and produced interleukin-2 (IL-2) 
in response to the encephalitogenic peptide (amino acids 1-11) of MBP 
presented in the context of H-2U. Despite these similarities, the clones 
differed in their ability to transfer EAE. Clones that produced greater 
incidence of disease and greater severity of clinical signs secreted mRNA 
for LT and high levels of cytotoxic factors. Clones that did not transfer 
disease produced low or undetectable levels of cytotoxic activity and LT 
mRNA (Powell et al., 1990). 
In subsequent in vivo experiments, Ruddle et al. demonstrated that 
inhibition of LT and TNF-a activity prevented clinical signs of paralytic 
V. 
disease (Ruddle et al., 1991). To block LT and TNF-a activity, they used 
TN3.19.12, a hamster monoclonal antibody that effectively neutralizes 
both exogenously produced LT and TNF-a in activated T cell culture 
supernatants and endogenously produced TNF in vivo (Sheehan, 1989). 
Ruddle et al. induced EAE in mice with LNC-8, an MBP-specific T cell line 
derived from the popliteal lymph nodes of an SJL/J mouse immunized 
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with porcine MBP. It was known that LNC-8 secreted both LT and TNF-a 
because culture supernatants from LNC-8 cells activated by ConA, a 
nonspecific mitogen, YCD3-1, an anti-CD3 antibody, and by MBP presented 
by irradiated syngeneic spleen cells were all cytotoxic to WEHI 164 cells, 
a target for both LT and TNF-a. The amount of cytotoxic activity in the 
culture supernatants increased over time of stimulation (measured at 8, 
24, and 48 hours), especially when LNC-8 cells were first activated with 
MBP and irradiated spleen cells. LT and TNF-a mRNA was isolated from 
LNC-8 cells activated by all three methods. TN3.19.12 anti-LT/TNF-a 
antibody completely neutralized WEHI 164 cytotoxic activity of 
supernatants obtained after all methods of activation of LNC-8 cells 
including MBP + spleen cells, Con A, and anti-CD3+ antibody (Ruddle et al., 
1991). 
Next, and even more importantly, Ruddle et al. inhibited LNC-8 
transfer of EAE by treatment of recipient mice with anti-LT/TNF-a 
antibody. In five different experiments, groups of 4 or 5 mice were 
injected intraperitoneally (IP) with 7.5-9 x 106 LNC-8 cells and then 
treated 48 hours later with either a single 300pg IP injection of 1) 
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TN3.19.12, 2) L2D39, a control hamster monoclonal antibody, or 3) PBS. 
Mice were observed daily for three weeks to document onset of clinical 
signs of EAE. The clinical scale used to grade the severity of EAE was as 
follows: 0 = normal, 1 = tail limpness, 2 = paraperesis with a clumsy gait, 
3 = hind limb paralysis, 4 = hind and fore limb paralysis, 5 = death. In all 
groups of mice, TN3.19.12 greatly reduced severity of disease and delayed 
disease onset compared to control antibodies. Whereas average disease 
scores for PBS and L2D39 injected animals were 2.6 and 2.2 respectively 
and average disease onsets were 6.2 and 7.8 days respectively, the 
average disease score for TN3.19.12 protected mice was 0.9 and the 
average disease onset was 8.6 days (Ruddle et al., 1991). 
In their next experiment, Ruddle et al. produced even more clinically 
apparent disease. They injected 12x10^ LNC-8 cells intravenously into 
groups of nine to ten mice and tried to block transfer at 48 hours post 
injection with 1 mg of 1) TN3.19.12, 2) anti-IL4 antibody, and 3) PBS. 
Average disease severity in the PBS and anti-IL4 treated animals was 3.9 
and 3.3 respectively while average disease severity in the TN3.19.12 
treated group was 0.9. The incidence of disease was also reduced from 
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89% in the PBS treated group to 20% in the anti-LT/TNF-a treated group. 
Several groups of mice were observed for two to three months after 
TN3.19.12 injection and the inhibition of EAE transfer proved to be 
long-lived. No mice developed disease if it had not occurred by day 12 
(Ruddle et al., 1991). 
Histopathology correlated well with degree of clinical disease. On 
limited histological examination, there was little or no meningeal 
infiltration or inflammatory cells surrounding cerebral venules in 
animals where LT and TNF-a activity was blocked. All mice from the 
groups that received LNC-8 cells and control antibodies or PBS that were 
examined had histologic signs of perivascular cuffing and infiltration 
consistent with their clinical signs (Ruddle et al., 1991). Thus 
anti-LT/TNF-a antibody prevents both the clinical and histologic 
manifestations of EAE. 
While other antibodies have been shown to block EAE, anti-LT/TNF- 
antibodies like TN3.19.12 may play the greatest role in treating MS itself 
because it binds T cell mediators rather than T cells themselves. Sriram 
et al. suppressed passively transfered EAE with injections of anti-IA 

antibodies (Sriram et at., 1987), Urban et al. blocked MBP peptide-induced 
EAE with an antibody to the V88 gene element of the CD4+ T cell receptor 
(Urban et al., 1988) and Rose et al. blocked passive transfer of EAE with 
IL2-PE40, a chimeric protein composed of human IL2 genetically fused to 
a modified form of Pseudomonas exotoxin lacking the cell recognition 
domain (Rose et al., 1991). In contrast to these previous experiments, 
TN3.19.12 does not inactivate all CD4+ T cells or even a major component 
of the T cell repertoire. Since LNC-8 is a cell line that contains at least 
two T cell populations that use different TCR 8 genes (Ruddle et al., 
1991), it can also be seen that TN3.19.12 activity is not limited to a 
single T cell clone. The non-specificity is important because in MS, 
although the number of TCR 8 genes used may be limited, it is certainly 
greater than one (Ruddle et al., 1991). Thus, rather than binding to 
specific T cell lines, TN3.19.12 probably inhibits the activity of cytokine 
mediators that are produced in vivo by activation of these 
antigen-specific T cells. 
However, the mechanisms by which this potentially very beneficial 
antibody inhibits the transfer of EAE remains unclear. It is possible that 

TN3.19.12 could inhibit the disease in part by binding to and eliminating 
LT and TNF-a bearing cells but this does not seem very likely since 
TN3.19.12 does not react with the membrane bound form of TNF-a on 
macrophages. TN3.19.12 could also inhibit transfer of disease by 
preventing the activities of soluble LT and TNF-a at various stages. LT 
and TNF -a could directly affect the activities of transfered and activated 
T cells, macrophages, and additional cells within the CNS such as 
astrocytes, microglia, and oligodendrocytes. Alternatively, the 
interactions of transfered T cells, recruited T cells, and cells indigenous 
to the CNS may be altered. TN3.19.12 may also prevent LT and TNF-a 
induction of an increase in MHC determinants on endothelial cells (Pober 
et al., 1987), or alteration of CNS permeability and of influx of 
inflammatory cells through an increase in cell adhesion molecules on the 
endothelium (Pober et al., 1987). In addition, TN3.19.12 may neutralize 
cytokines secreted by inflammatory cells which cross the blood brain 
barrier and which directly affect the myelin sheath and influence 
viability of oligodendrocytes. 
To understand exactly how anti-LT/TNF-a antibody blocks the 

induction of EAE, it is first necessary to study the time course, 
histological pattern, and specificity of T cell migration into the CNS 
during EAE induction. Since the CNS of a healthy individual is normally 
"immunologically privileged" and contains very few native lymphocytes or 
expressed MHC molecules (Hickey, 1991), it is unclear how, when, and why 
T cells gain entry into the CNS and how they induce disease. In an elegant 
series of experiments, Hickey showed that regardless of their antigen 
specificity, their MHC restriction element, their MHC compatibility, or 
their phenotype, T cells can enter the CNS as long as they are activated. 
He injected 1) activated CD4+ T cells specific for MBP, 2) activated T 
cells with the same phenotype and using the same restriction element but 
specific for calf thymus histone, 3) activated pooled lymph node and 
splenic T cells of both CD4+ and CD8+ phenotypes and 4) resting pooled 
lymph node and splenic T cells into syngeneic rats and looked at 
infiltration into the CNS. The injected cells, whether specific for a CNS 
antigen or not, entered the CNS with the same kinetics and reached peak 
concentrations between 9 and 12 hours following injection. Resting 
lymphocytes never crossed the blood brain barrier. After twelve hours 

post injection, the concentration of cells found in the CNS decreased, 
however, and only cells capable of recognizing their antigen among the 
proteins of the CNS, such as MBP-specific T cells, remained (Hickey, 
1991). 
One problem with this experiment, however, is that Hickey used a 
nonspecific T cell antibody to detect the injected T cells within the CNS. 
Since the rat normally contains very low but detectable levels of T cells 
in its CNS even without the injection of additional cells into the 
circulation, it is impossible to be certain that the cells injected into the 
circulation were the ones detected in the CNS. In fact, Hickey looked at 
spinal cords up to 72 hours post injection and found levels of presumed 
MBP-specific T cells to be only slightly greater than those of endogenous 
T lymphocytes (Hickey, 1991). 
In an attempt to label only injected T cells, Hickey injected the same 
groups of Lewis cells into a DA rat and used a monoclonal antibody that 
detected only the Lewis class I (RT-IA) molecule. He thus followed the 
kinetics of Lewis cells in DA CNS and found that activated T cells will 
enter the CNS parenchyma rapidly with peak concentration between 9 and 
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12 hours and depart rapidly if they do not recognize their antigen. In this 
experiment, however, he could not determine whether MBP-specific T 
cells remained in the CNS after recognizing their antigen since the MHC of 
the DA rat is incapable of presenting any CNS antigen to Lewis 
lymphocytes in the correct MHC context. Hickey also did not look for 
lymphocytes in the brains of either Lewis or DA rats; he looked only at 
their spinal cords (Hickey, 1991). 
Cross et al. used a different approach to examine the problem of T 
cell infiltration into the CNS. They used [14C]thymidine to label 
MBP-sensitized lymphocytes from MBP-immunized mice before 
transfering them to naive syngeneic recipients. They looked at sections 
of brain and spinal cord 24 hours prior to and during initial clinical 
v 
disease and their results confirmed what Hickey's suggested; they found a 
small number of labelled T lymphocytes around venules of the blood brain 
barrier up to two weeks after disease onset. However, at no time point 
did [14C]thymidine labelled cells represent a sizable portion of the 
perivascular inflammatory cells commonly associated with clinical 
disease. Even in areas of extensive myelin pathology, radiolabelled cells 

within the CNS were very rare. While there were many monocytes, 
macrophages, and PMNs surrounding venules, the mean percentage of 
labelled cells was 2.3% in the lumbar cord, 1.5% in the brainstem, and 
0.5% in the brain parenchyma. When encountered, labelled cells were 
usually in close proximity to capillaries and small venules (Cross et al., 
1990). 
For controls, Cross et al., labelled cells from immunized mice with 
[14C]thymidine following a three day stimulation period with purified 
protein derivative (PPD) of tuberculin prior to transfer. Mice did not 
become ill and no labelled cells were found in the CNS from days 5-27 
post transfer. Since Hickey already suggested that activated T cells not 
specific for a CNS antigen may enter and leave the CNS within 48 hours, it 
v 
is no surprise that Cross et al. did not find labelled PPD sensitive cells in 
the CNS after the fifth day post transfer (Cross et al,. 1990). Thus, Cross 
et al. left out an essential part of this experiment- they did not look at 
tissue in the immediate period after T cell transfer. 
Another problem with this experiment is the reliability of the label. 
Although Cross et al. suggest that MBP-specific cells act exclusively 

from a perivascular location to orchestrate the influx of inflammatory 
cells (Cross et al.t 1990), it is possible that the cells divide rapidly 
immediately upon entering the CNS parenchyma and dilute out the label. 
For how can T cells find their antigen if they only remain near the blood 
vessels? EAE pathology is not solely confined to perivenules; it is found 
deep in the brain and spinal cord parenchyma (Raine et al., 1980). 
In our series of experiments, we attempt to address the technical 
problems of these previous experiments and study by histological 
analysis the induction of EAE and its alleviation by anti-LT/TNF-a 
antibody. We use a new and highly effective and specific cell label, 
Di-I-C to explore not only the timing of T cell entry into the CNS in EAE 
but also T cell migration and distribution within the CNS. This lipid 
soluble dye has never been used before in T cell homing experiments and 
it is extremely important since it partitions into the phospholipid bilayer 
and allows visualization of the entire cell. Since it labels the T cell for 
prolonged periods of time, it permits tracking of T cells within the CNS. 
This dye also permits, for the first time, studies of the mechanism of 
TN3.19.12 anti-LT/TNF-a antibody inhibition of EAE. In these 

experiments, we demonstrate the effects of TN3.19.12 on T cell entry 
into the CNS and define a role for LT and TNF-a in EAE and possibly in MS 
itself. 

Materials and Methods 
Di-I-C Labelling 
Di-I-C(18)3 or 1' dioctadecyl 3-3-3'-3'tetramethylenolcarbocyanine 
perchlorate was obtained from Molecular Probes Inc., P.O. Box 22010, 
4849 Pitchford Avenue, Eugene, OR, 97402 (503-344-3007) cat# 282. 
lOOpg units cost $75.00. It was stored at -209C in powdered form and 
wrapped tightly in aluminum foil to keep out light. It is a cationic 
membrane probe that partitions into the phospholipid bilayer and is 
non-invasive and non-toxic. It divides with the dividing cell and has 
stained MBP-specific FI 28 T cells in culture for up to two months with 
progressively diminishing signal (Ruddle et al., unpublished results). 
800pg-1 mg was dissolved per 1 ml of ethanol. The solution was agitated 
v 
and heated in a 379C water bath until the dye went into solution. 15pl of 
this solution was added to each ml of 5 x 106 cells + 10% fetal calf 
serum (FCS) + RPMI 1640 media. Cells fluoresced distinctly under UV 
with filters that excited rhodamine or fluorescein compounds. 
LNC-8 and V817- T Cell Proliferation Assay 
This assay was performed to confirm that both LNC-8 and V617" T 

cells could be stimulated with porcine MBP, irradiated syngeneic spleen 
cells, and recombinant IL-2. VR17' is a cell line derived from the LNC-8 
cell line that secretes both LT and TNF-a and induces EAE just as 
effectively as LNC-8 cells (Clark et al., unpublished observation). Both 
types of T cells were plated at 2 x 10^ per well with 10% FCS in 96 well 
plates and stimulated for 48 hours with either lOpg/ml porcine MBP + 
irradiated syngeneic spleen cells, Ipg/ml recombinant IL-2 + lOpg/ml 
porcine MBP + irradiated syngeneic spleen cells, or 5pg/ml Con A. Cells 
were then counted with a Coulter cell counter. LNC 8 and V617' cells 
that were not stimulated with any of the above agents were grown for 48 
hours in 10% FCS and used as controls. 
T Cell Culture and Activation 
V 
LNC-8 and V317" T cell lines reactive to MBP were obtained from 
Robert Clark (University of Connecticut) and activated every other week 
prior to injection. Cells were fed RPMI 1640 media + 10% FCS twice a 
week on Monday and Friday, recombinant IL-2 (Ipg/ml; Amgen) every 
other Monday, and recombinant IL-2, porcine MBP (lOpg/ml; Calbiochem) 
and irradiated syngeneic spleen cells every other Friday. Cells were 
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injected at intracardiac (1C) and intraperitoneai (IP) sites of SJL mice 
Tuesday morning following Friday activation with MBP, spleen cells, and 
IL-2 and refeeding on Monday with IL-2. 
T Cell Labelling and Injection 
On Tuesday morning, cells were harvested from plates and flasks, 
spun down, resuspended in RPMI and 10% FCS, and counted. Cells were 
dyed in RPMI 1640 and 10% FCS at a volume of 5 x 10®/ml for one hour in 
a 37eC water bath. They were agitated once every ten minutes to keep the 
dye evenly distributed. Three washes in 1% PBS were performed. Cells 
were then spun down and concentrated to a volume of 50 x 10®/ml in 1% 
PBS for 1C injection or 10 x 106/ml in 1% PBS for IP injection. Depending 
on the experiment, mice received anywhere from 10-15 x 10® cells (1-1.5 
ml IP or 0.2 ml 1C) 1C injection was done free hand. Undyed cells, 
injected in equal volume and numbers, were used as controls. To 
determine if T cells transfered dye to spleen cells in culture, dyed LNC-8 
and V317" cells were cultured with undyed, irradiated spleen cells for 1 




Transfer of EAE 
Two separate experiments were performed to test the effectiveness 
of LNC-8 and VG1T T cell induction of EAE with and without dye. 14 
female, 3 month old, SJL/J mice were used in each experiment and all 
animals were evaluated for clinical signs of EAE daily for at least three 
weeks after injection of cells. The clinical scale was as follows: 0 = 
normal, 1 = limp tail, 2 = paraparesis with a clumsy gait, 3 = hind limb 
paralysis, 4 = fore and hind limb paralysis, 5 = death. Animals used for 
histology were taken from these two experimental groups and 4 other 
experimental groups of 2-4 animals each described below. Results were 
compared by two-tailed T tests. 
TN3.19.12 Antibody Injection 
3 mice from the two largevexperimental groups were injected IP 
with 1 mg of TN3.19.12 anti-LT/TNF-a antibody in 0.5 ml of 1% PBS 48 
hours after T cell injection. TN3.19.12 was injected only into mice which 
had received dyed cells. The antibody is as described in (Sheehan et al., 
1989). Briefly, monoclonal antibody to murine TNF was produced after 
immunization of Armenian hamsters with purified E.Coli-derived 
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rMuTNF-a. Antibody from clone TN3.19.12 was purified and was found to 
inhibit 100% of the lytic activity of either recombinant or natural 
MuTNF-a at an antibody input of 25 ng/U. TN3.19.12 also inhibited all the 
lytic activity in culture supernatants from a variety of T cell sources, 
including activated T cell clones and T cell hybridomas (all of which 
expressed high levels of TNF-a and LT mRNA). Western blot analysis was 
used to document the physical form(s) of MuTNF recognized by TN3.19.12. 
Recombinant and macrophage-derived TNF displayed identical patterns of 
a single band with Mr 17 kDa. In contrast, T cell culture supernatants 
exhibited patterns consisting of two bands with Mr 17 and 24.7 kDa, the 
latter consistant with that of LT. These data suggest that TN3.19.12 
recognizes both MuTNF-a and LT (Sheehan et al., 1989) 
Histology and Tracking of Dyed T Cells 
In addition to the two large experimental groups, four other 
experimental groups of 2-4 SJL mice each were used for histology and 
tracking of dyed T cells. Mice were killed 8 hours (1 mouse), 9 1/2 hours 
(1), 11 hours(2), 12 hours (1), 13 hours (2), 14 hours (1), 18 hours (2), 2 
23 

days (2), 1 week (1), 10 days (2), or two weeks (2) after dyed LNC-8 or 
VB17" T cell injection and/or TN3.19.12 antibody injection. All mice 
killed one week or later post injection had clinical disease scores of at 
least 2.0. Mice were anesthetized with metofane and perfused with 10% 
formalin or 4% paraformaldehyde in 1% PBS. Brain, spinal cord, iymph 
nodes, spleen, liver, kidney, and lungs were removed and kept in 10% 
formalin or 4% paraformaldehyde for 1 day at 4SC. Organs were then 
placed in a 20% sucrose solution in 1% PBS and kept at 4QC for half a day. 
Tissue was then frozen in Tissue Tek and 10-15pm sections were cut on a 
cryostat and examined under filters that excite rhodamine and/or 
fluorescein light for presence and distribution of T cells. Amount of T 
cells per high power field were qualitatively scored from 1 + to 4+. Some 
brain and spinal cord sections were stained with hematoxylin and eosin 





LNC-8 and V81T Cell Proliferation Assay 
Although both LNC-8 and VG17' cells have both been shown to 
proliferate in response to MBP + IL-2 + spleen cells (Ruddle et al., 1990, 
Clark et al., unpublished results), this assay was done to determine 
whether our culture and activation methods were adequate. First, 
proliferation of LNC-8 and VG17" cells in response to various stimulating 
agents was measured against proliferation of unstimulated LNC-8 and 
VG17‘ cells (Table 1). On the average, LNC-8 cells stimulated with 
either MBP + spleen cells or IL-2 + MBP + spleen cells proliferated 279x 
more than unstimulated LNC-8 cells. VG17" cells stimluated with either 
MBP + spleen cells or IL-2 + MBP + spleen cells proliferated 188x more 
than unstimulated VG17" cells. LNC-8 and V317" cells stimulated with 
Con A rather than MBP + spleen cells + IL-2 only proliferated 25x and 30x 
more than non-stimulated LNC-8 and V317" cells. 
T Cell Dyeing 
LNC-8 and VG17' cells were successfully dyed with Di-I-C. As 
shown in Figure 1, Di-I-C covers the entire cell and is easily visualized 
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under a filter that excites fluorescein light. This cell is from a one week 
culture and has been transfered from the culture dish onto a slide. As 
noted in Materials and Methods, Di-I-C stains dividing cells in culture and 
continues to stain cells at least up to two months in culture. In addition, 
Di-I-C does not transfer its label to spleen cells in culture. Figure 2 
shows LNC-8 cells which have been dyed and added to irradiated spleen 
cells in culture. This photomicrograph was taken after two weeks in 
culture. While dyed LNC-8 cells fluoresce very brightly under a rhodamine 
filter, spleen cells are much smaller than T cells and fluoresce minimally 
or not at all. Thus, if it were possible that spleen cells inadvertently 
accompanied T cells across the blood brain barrier, they would not be 
visualized with this dye. 
Transfer of EAE 
These experiments showed that Di-I-C did not interfere with 
transfer of EAE. The average day of onset and average maximum clinical 
score of mice injected with dyed LNC-8 or V317' T cells were 
comparable to those of mice injected with undyed cells (Table 2). Of 25 
animals injected with either LNC-8 or V817‘ T cells and no TN3.19.12 
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antibody in two separate experiments, the average day onset of disease 
for dyed cells injected 1C (8 animals) was 4.0, for dyed cells injected IP 
(8 animals) was 7.2 (p <0.010), and for undyed cells injected 1C and IP (9 
animals) was 6.7. (There was no statistically significant difference 
between dyed cells injected IP and undyed cells injected 1C & IP). The 
average maximum score for dyed cells injected 1C was 5.0, for dyed cells 
injected IP was 2.5 (P <0.010), and for undyed cells injected 1C and IP was 
2.2. (There was no statistically significant difference between dyed 
cells injected IP and undyed cells injected 1C & IP). Thus Di-I-C did not 
interfere with onset or severity of disease. Mode of injection however, 
did influence the transfer of EAE. T cells injected 1C rather than IP 
induced disease more quickly and with greater severity. 
TN3.19.12 Antibody Injection 
To make certain that TN3.19.12 anti-LT/TNF-a alleviates the 
severity of EAE induced by dyed T cells, 3 animals were injected with 
TN3.19.12 IP 48 hours after dyed T cell 1C injection. Results were 
exactly as demonstrated by Ruddle et al. 1990 with undyed T cells; 
TN3.19.12 reduced the clinical grade of EAE and slightly delayed the day 
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of disease onset (Table 2). Average day of onset with TN3.19.12 antibody 
injection was 4.7 (P < 0.050 when compared with dyed cells injected 1C 
without antibody) and average maximum disease score was 1.0 (P <0.010 
when compared with dyed cells injected 1C without antibody). 
Histology and Tracking of Dyed T Cells 
The most important part of this experiment is the qualitative 
evaluation of T cell migration and distribution within the CNS. To study 
this, we examined the brain and spinal cords of mice at various intervals 
after dyed T cell injection IP and/or 1C. Mice used for time points of 8 
hours (1), 9 1/2 hours (1), 11 hours (2), 12 hours (1), 13 hours (2), 14 
hours (1), 18 hours (2) and 2 days post injection (2) were taken from 4 
experimental groups of 2 to 4 animals each and mice used for 1 week (1), 
10 day (2), and two week (2) time points were taken from the two large 
experimental groups of 14 animals each. 
At eight hours post injection, numerous brightly labelled T cells 
were seen throughout the brain and spinal cord (score = 2+). Figure 3 
shows the spinal cord of an animal killed 8 hours post injection of dyed 
VI317“ T cells examined under a filter that excites rhodamine light. A 
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brightly dyed T cell is seen in the spinal cord parenchyma. More dyed T 
cells are seen throughout the brain and spinal cord at 9 1/2 hours post 
injection (score = 3+). Figure 4a shows dyed VB17" T cells throughout 
the brain parenchyma and Figure 4b shows a dyed VB17" T cell in the 
spinal cord parenchyma of mice killed 9 1/2 hours post injection. These 
cells are seen under a filter that excites rhodamine. 
Upon qualitative analysis, T cell infiltration into the CNS seems to 
peak at 11 hours post injection (score = 4+). Figure 5a shows dyed LNC-8 
cells in the brain of a mouse killed 11 hours post injection. Here, there 
are numerous dyed cells within the brain parenchyma. Di-I-C outlines 
their membranes so well that one can almost see them "walking" through 
the brain, in active pursuit of their antigen, myelin basic protein. Figure 
5b shows an LNC-8 cell at high magnification most likely in this active 
process of tracking down its specific antigen. 
The number of T cells in the brain and spinal cord gradually dwindle 
at 12, 13, and 14 hours post injection. Figure 6 shows a mouse brain at 
12 hours post injection of dyed VI317" cells under a filter that excites 
rhodamine light. The number of cells is diminished at this time in 
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comparison with previous times (score = 1+). At 18 hours post injection, 
no dyed T cells can be seen in the brain and spinal cord parenchyma. 
Accordingly, no dyed T cells could be found within the brain or spinal 
cords of mice killed at 2 days, 1 week, 10 days or 2 weeks post injection. 
Dyed T cells could be found in other organs of mice killed up to 2 weeks 
post injection, however. Numerous dyed T cells were seen in the lymph 
nodes, lungs, liver, and spleen of mice killed anytime from 8 hours post 
injection to 2 weeks post injection. This result implies that Di-I-C did 
not fade or dilute its label with cell division but rather that most or all 
labelled MBP-antigen specific T cells were no longer present within the 
CNS just 6 hours after they arrived. 
Another important point is that TN3.19.12 probably does not work by 
eliminating T cells bearing LT and TNF-a because the antibody was 
injected 48 hours after injection of T cells, long after they had 
infiltrated into and apparently left the CNS. Thus, TN3.19.12 most likely 
interacts with soluble forms of LT and TNF-a and prevents their 
activities at various stages of disease transfer. 
To examine the histological effects of TN3.19.12, several sections of 
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brain and spinal cord from mice with advanced clinical disease and from 
mice who had received the TN3.19.12 antibody were stained with 
hematoxylin and eosin and examined under a light microscope at 1 week, 
10 days, and 2 weeks post injection. While there was marked 
perivascular infiltration of inflammatory cells in the brains and spinal 
cords of mice that did not receive the antibody, this infiltration was 
much reduced in antibody-injected animals. Thus, we demonstrate that 
TN3.19.12 blocks recruitment of macrophages, neutrophils and other 
inflammatory cells that may play a large part in EAE induction. As 
reported earlier by Ruddle et al. in their EAE TN3.19.12 antibody study, 
(Ruddle et. al., 1991) the histological picture of EAE and its alleviation by 




Table 1: T Cell Proliferation Assay 
Cell Type Stimulating Agent Proliferation Ratios 
LNC-8 MBP+SC 251 
LNC-8 MBP+SC+IL-2 307 
LNC-8 Con A 25 
VB17" MBP+SC 174 
VB17’ MBP+SC+IL-2 201 
V317’ Con A 30 
This table demonstrates the response of LNC-8 and V617' cells to various stimulating agents. 
LNC-8 and V317' cells were incubated in 10% FCS and stimulated for 48 hours with either 
lOpg/ml porcine MBP + irradiated spleen cells, recombinant IL-2 + lOpg/ml porcine MBP + 
irradiated spleen cells, or 5pg/ml Con A. Non-stimulated LNC-8 and VB17' cells were used to 
establish baseline incorporation for the proliferation ratios. 
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Table 2: Clinical Evaluation of EAE Transfer 




Dyed cells 1C (8 animals) 4.0 5.0 
Dyed cells IP (8 animals) 7.2 2.5 
Undyed cells IC&IP (9 animals) 6.7 2.2 
Dyed cells 1C with TN3.19.12 
antibody (3 animals) 
4.7 1.0 
This table demonstrates the average day onset and average maximum score of dyed T cells 
injected 1C, dyed cells injected IP, undyed cells injected 1C and IP, and dyed cells injected 1C with 
TN3.19.12 antibody. When average day onset and average maximum score of dyed cells injected 
1C and dyed cells injected IP were compared by two-tailed t tests, a p value of <.010 was 
obtained, p <.010 when dyed cells injected 1C with TN3.19.12 antibody were compared to dyed 
cells injected IP, p < 0.05 when average day onset of dyed cells injected 1C with and without 
TN3.19.12 were compared, and p < .010 when average maximum score of dyed cells 1C with and 
without TN3.19.12 were compared. There was no statistically significant difference between 





















Figure 1: LNC-8 cell that has been dyed with Di-I-C and kept in culture for 
one week. Photographed under a filter that excites flourescein. 
Magnification = 25X. 
Figure 2: LNC-8 cells that have been dyed with Di-I-C, added to irradiated 
spleen cells in culture, and kept in culture for two weeks. Photographed 
under a filter that excites rhodamine. Magnification = 40X. 
Figure 3: Spinal cord of an animal killed 8 hours post injection of VG17' 
cells dyed with Di-I-C. Photographed under a filter that excites 
rhodamine. Magnification = 25X. 
Figure 4a: Brain of a mouse killed 9 1/2 hours post injection of V817' 
cells dyed with Di-I-C. Photographed under a filter that excites 
rhodamine. Magnification = 10X. 
Figure 4b: Spinal cord of a mouse killed 9 1/2 hours post injection of 
VB17' cells dyed with Di-I-C. Photographed under a filter that excites 
rhodamine Magnification = 25X. 
Figure 5a: LNC-8 cells dyed with Di-I-C in the brain of a mouse killed 11 
hours post injection. Photographed under a filter that excites flourescein. 
Magnification = 25X. 
Figure 5b: LNC-8 cells dyed with Di-I-C in the brain of a mouse killed 11 
hours post injection. Photographed under a filter that excites flourescein. 
Magnification = 25X. 
Figure 6: V817" cell dyed with Di-I-C in the brain of a mouse killed 12 
hours post injection. Photographed under a filter that excites rhodamine. 




In these experiments, we demonstrate for the first time a highly 
effective way to visualize T cell entry into the CNS and to document 
histologically the events preceeding the induction of EAE. We use a T cell 
dye that does not interfere with transfer of EAE in any way and allows us 
to time T cell homing to the CNS and observe T cell migration within the 
CNS. We also show that most likely the anti-LT/TNF-a antibody, 
TN3.19.12 does not work by binding to antigens on the surface of specific 
T cells but rather alleviates clinical and histological signs of disease by 
binding to soluble forms of LT and TNF-a. 
Di-I-C has never before been used in T cell homing experiments and is 
a much better cell marker than radionucleotide labels or nonspecific T cell 
antibody markers that label T cells only in histological sections of brain 
and spinal cord. It divides with the dividing cell and does not dilute out as 
radionucleotide labels often do (Wojcieszyn et al., 1983). After two 
weeks in vivo, it was visible in the lymph nodes, lungs, liver and spleen of 
mice and it was visible in vitro after two months in culture. It does not 
transfer to spleen cells in culture and outlines nicely the entire cell 
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membrane so one can follow T cell movement within the CNS. Moreover, it 
does not interfere with the induction of EAE or the alleviation of EAE by 
the TN3.19.12 antibody. It is also inexpensive, non-toxic and easy to use. 
Thus, it will be very helpful in future EAE and T cell homing experiments. 
Due to the effectiveness of Di-I-C, we were able to define accurately 
the timing of T cell migration into the CNS. Unlike Cross et al. who failed 
to look at tissue in the immediate period after T cell transfer, we looked 
at CNS tissue from 8 hours post injection to two weeks post injection. 
Almost 5 days before their first time point, T cell infiltration into the 
CNS had already peaked and subsided. In addition, while Cross et al. found 
labelled cells only in close proximity to capillaries and small venules, we 
found them scattered evenly throughout the brain and spinal cord 
parenchyma. Perhaps if Cross et al. had looked earlier, they too would 
have found numerous scattered cells throughout the CNS. It is unclear why 
we did not find any residual cells in the CNS after 14 hours post injection. 
Although our cells could somehow have lost their label, this is not likely 
because dyed cells were seen in many other parts of the body including 
lymph nodes, lungs, liver, and spleen up to two weeks post injection. 
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Since Cross et al. found some T cells in the brain and spinal cord, albeit 
very few (Cross et al., 1991), it is surprising that our technique did not 
locate them. Likewise, Hickey et al. also found T cells in spinal cords up 
to 72 hours post injection. We have no way of telling in his case however, 
whether or not these T cells were host-derived since he did not label T 
cells before he injected them but rather used a non-specific T cell 
antibody on fixed spinal cord slices. Nonetheless, a larger and more 
detailed histological analysis of CNS tissue is needed with meticulous 
studies of brain and spinal cord for lingering MBP-specific T cells. 
Di-I-C also enabled us to demonstrate T cell movement within the 
CNS- something neither Hickey nor Cross examined due to their cell label 
constraints. In Figures 3 through 6, one can see the MBP-specific T cells 
tracking through the brain and spinal cord, probably looking for their 
correct antigen. This picture correlates well with the idea that T cells 
having various specificities are able to cross the blood brain barrier. Yet 
only those that track down their specific antigens are able to remain 
within the CNS and to initiate and/or orchestrate the disease process. A 
combination of Di-I-C and a marker for blood vessels will facilitate 
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further studies of T cell movement within the CNS. 
One helpful experiment in further studies would be to examine 
non-MBP-specific T cell migration into the CNS. It would be important to 
see whether non-MBP-specific T cells would home to the CNS and if they 
would leave soon after failing to locate their antigen. Hickey predicts this 
phenomenon in his review article; yet he cannot properly test it because he 
does not use a specific T cell label. Another new dye, Di-O, which has 
similar chemical properties to Di-I-C but is best visualized under a 
fluorescein filter, will enable us to label two separate T cell populations 
at the same time and to look at their differing kinetics. By labelling 
non-MBP-specific T cells with Di-0 and LNC-8 or VI317- cells with Di-I-C, 
we could determine if T cells do stay in the CNS once they find their 
correct antigen or if a second wave of infiltratrion by specific T cells 
occurs. 
Another issue that needs to be addressed in further studies is the 
nature and timing of the inflammatory cell recruitment. It is important to 
know when and how neutrophils and macrophages cross the blood brain 
barrier and what role they play in the disease process. This could be 
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accomplished by staining every other CNS section with hematoxylin and 
eosin and/or antibodies to inflammatory cells. We could then quantify the 
effects of TN3.19.12 on CNS inflammation. For example, TN3.19.12 may 
prevent alteration of CNS permeability by LT and TNF-a, it might prevent 
specific cell types from being recruited into the CNS or it might reduce LT 
and TNF-a-induced myelin breakdown. 
TN3.19.12 might also prevent a LT and TNF-a-mediated increase of 
cell adhesion molecules on the endothelium of vessels of the blood brain 
barrier. To examine this possibility, we can study the regulation and 
expression of ICAM and other adhesion molecules in EAE. This would be 
fairly straightfoward to do within our experimental design. We could 
simply block the expression of ICAM and other adhesion molecules with 
monoclonal antibodies and then monitor the inflammatory cell influx 
histologically. We could also look clinically for alleviation of disease. In 
addition, we could study how TN3.19.12 affects adhesion molecule 
expression. 
We can add another piece to this puzzle by discovering when and how 
LT and TNF-a themselves are secreted in EAE. Specific T cells may 
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secrete LT and TNF-a in response to interacting with their proper CNS 
antigen. Macrophages and neutrophils may secrete TNF-a as part of their 
general inflammatory response. Other resident CNS cells may also secrete 
LT and TNF-a after activation. It is easiest to study the secretion of LT 
and TNF-a by examining the stages in which TN3.19.12 anti-LT/TNF-a 
antibody blocks EAE transfer. 
In conclusion, these studies have brought us closer to understanding 
the process of EAE. We now understand when T cells specific for MBP 
cross the blood brain barrier and when they are present within the CNS in 
greatest numbers. We also now know that TN3.19.12 probably alleviates 
disease by blocking the actions of soluble LT and TNF-a. Since TN3.19.12 
is so effective and is non-specific, an antibody like it generated against 
human tumor necrosis factors may be very helpful in the treatment of MS. 
Thus, we have not only begun to piece together the exact mechanism of 
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